10 research outputs found

    Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry

    Get PDF

    Rare Earth metal complexes supported by ancillary imidazolin-2-iminato ligands

    No full text
    The coordination chemistry of imidazolin-2-iminato ligands towards rare earth metal atoms is reviewed. The structural characterization of a large number of mono-, bis- and tris(imidazolin-2-iminato) complexes - in most cases scandium, yttrium, gadolinium, and lutetium complexes - reveals almost exclusively the formation of mononuclear complexes with very short metal-nitrogen bonds, which confirms the ability of imidazolin-2-iminato ligands to efficiently act as imidotype 2ξ,4Ï-electron donors. In particular, mono(imidazolin-2-iminato) metal dichlorides proved to be excellent starting materials for the introduction of alkyl, amido, cyclopentadienyl, cyclooctatetraenyl, and car-boranyl ligands and also for the preparation of efficient pre-catalysts for ring-opening, hydroamination and hydrosilylation reactions, which allow to establish imidazolin-2-iminato ligands as novel valuable members of the growing family of ancillary ligands in organo rare earth metal and organolanthanide chemistry. In addition, the coordination chemistry of several imidazolin-2-imine-hybrid ligands such as cyclopentadienyl-imine and pincer-type diimine ligands is described, and the structural characterization of the resulting complexes indicates that also neutral imidazolin-2-imines act as strong amido-type donor ligands towards rare earth metal ions. © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

    Mixed Imidazolin-2-iminato–Cp* Thorium(IV) Complexes: Synthesis and Reactivity Toward Oxygen-Containing Substrates

    No full text

    Chronic coronary syndromes without standard modifiable cardiovascular risk factors and outcomes: the CLARIFY registry

    No full text
    Background and Aims: It has been reported that patients without standard modifiable cardiovascular (CV) risk factors (SMuRFs—diabetes, dyslipidaemia, hypertension, and smoking) presenting with first myocardial infarction (MI), especially women, have a higher in-hospital mortality than patients with risk factors, and possibly a lower long-term risk provided they survive the post-infarct period. This study aims to explore the long-term outcomes of SMuRF-less patients with stable coronary artery disease (CAD). Methods: CLARIFY is an observational cohort of 32 703 outpatients with stable CAD enrolled between 2009 and 2010 in 45 countries. The baseline characteristics and clinical outcomes of patients with and without SMuRFs were compared. The primary outcome was a composite of 5-year CV death or non-fatal MI. Secondary outcomes were 5-year all-cause mortality and major adverse cardiovascular events (MACE—CV death, non-fatal MI, or non-fatal stroke). Results: Among 22 132 patients with complete risk factor and outcome information, 977 (4.4%) were SMuRF-less. Age, sex, and time since CAD diagnosis were similar across groups. SMuRF-less patients had a lower 5-year rate of CV death or non-fatal MI (5.43% [95% CI 4.08–7.19] vs. 7.68% [95% CI 7.30–8.08], P = 0.012), all-cause mortality, and MACE. Similar results were found after adjustments. Clinical event rates increased steadily with the number of SMuRFs. The benefit of SMuRF-less status was particularly pronounced in women. Conclusions: SMuRF-less patients with stable CAD have a substantial but significantly lower 5-year rate of CV death or non-fatal MI than patients with risk factors. The risk of CV outcomes increases steadily with the number of risk factors
    corecore